Phycoil Biotechnology International Inc.
June 16, 2025
Company Presentation

Phycoil Biotechnology International Inc., based in Fremont, California, is an innovative biotech company leveraging a proprietary microbial platform to develop sustainable, plant-based bio-products. With a unique collection of proprietary strains and expertise in synthetic and industrial biotechnology, Phycoil produces high-value omega-3, -6, and -9 fatty acids and functional ingredients for nutraceuticals, personal care, and food applications. Its advanced fermentation technologies use microalgae cultivated via eco-conscious processes that preserve marine ecosystems. Phycoil’s product offerings target key health areas such as inflammation and brain health, delivering bioactives that support cognitive performance and immune balance. Backed by a robust patent portfolio and international operations, including its South Korean subsidiary, Phycoil is advancing environmentally responsible, health-promoting innovations at global scale.
.png)
Company HQ City:
Fremont
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2009
Lead Product in Development:
A unique portfolio of rare and structurally optimized omega-3, -6, and -9 fatty acids, developed through proprietary microalgae fermentation. These bioactives are targeted for clinically relevant applications in cardiovascular health, cognitive function, and healthy aging—addressing key areas of global unmet need.
CEO
Dr. Chung Soon Im
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
5 unlicensed products
When you expect your next catalyst update?
Phycoil’s next major inflection point is the scale-up and commercialization of its lead omega-3, -6, and -9 fatty acid formulation, with initial clinical validation studies planned for Q3 2025. This milestone will enable strategic licensing opportunities and commercial partnerships in the nutraceutical and functional health sectors. Additionally, expansion of our biomanufacturing capacity in Korea is expected to further de-risk production and accelerate go-to-market timelines.
What is your next catalyst (value inflection) update?
September 2025
Primary Speaker